Trials / Completed
CompletedNCT04052451
The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- NuBiyota · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study will measure the effects of MET-2 on symptoms of depression and anxiety using pre- and post-treatment scores for overall depression and anxiety and other symptoms of depression, such as sleep and anhedonia.
Detailed description
This study will measure the effects of MET-2 on symptoms of depression and anxiety using pre- and post-treatment scores for overall depression and anxiety and other symptoms of depression, such as sleep and anhedonia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MET-2 | Subjects will take study medication once daily for the duration of the study |
Timeline
- Start date
- 2019-05-16
- Primary completion
- 2020-05-01
- Completion
- 2020-05-01
- First posted
- 2019-08-09
- Last updated
- 2020-08-11
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04052451. Inclusion in this directory is not an endorsement.